B7-33 Peptide: The Biased Relaxin Agonist Fighting Fibrosis

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

B7-33 is one of the most discussed research peptides in fibrosis science today, and for good reason. It is a single-chain peptide derived from the B-chain of the human hormone H2 relaxin, engineered to keep relaxin’s anti-scarring action while shedding the parts of its signalling linked to unwanted cardiovascular and proliferative effects. In the laboratory, B7-33 behaves as a “biased agonist” at the relaxin receptor RXFP1, a property that has made it a magnet for preclinical researchers studying organ scarring. This guide explains what B7-33 is, how it works at the receptor level, what the published animal and cell data actually show, and how researchers handle it in the lab. All findings here are preclinical only.

Reviewed by the MedsBase Editorial Team · Last updated: 24 May 2026 · For research and educational use only.

On This Page

• What Is B7-33?
• How Does B7-33 Work? (Biased RXFP1 Agonism)
• Key Benefits & Uses of B7-33
• B7-33 Side Effects, Safety & Dosage
• What Does the Research Say?
• B7-33 vs Relaxin and Other Anti-Fibrotic Approaches
• How to Use B7-33 — Practical Guidance
• Frequently Asked Questions
• The Bottom Line

What Is B7-33?

Native human relaxin (H2 relaxin) is a two-chain hormone best known for softening connective tissue during pregnancy. Beyond that role, scientists noticed relaxin also reduces tissue scarring. The catch is that the full hormone is complex to manufacture and triggers a broad set of effects, some of them unwanted in a research or therapeutic setting.

The peptide strips relaxin down. Researchers took just the B-chain — the part that contacts the receptor — and stabilised it as a single chain. The result is a smaller, simpler molecule that retains the anti-scarring signal. Because it is derived from, rather than identical to, the parent hormone, the compound is correctly described as a relaxin analogue.

The name itself is a clue to its origin. “B7-33” reflects the residues of the relaxin B-chain that the molecule preserves, with chemical modifications that lock the single chain into a stable, receptor-active shape. That engineering is what lets a fragment of a two-chain hormone keep working on its own.

Importantly, the peptide has not been tested in humans. Everything known about it comes from cell cultures and rodent studies. It is sold as a research-grade reagent for laboratory use, not as a medicine, supplement, or treatment for any condition. Whenever you see claims about its effects, assume they describe a dish or a mouse — not a patient.

How Does B7-33 Work? (Biased RXFP1 Agonism)

To understand the peptide you need to understand the receptor it targets. The RXFP1 receptor (Relaxin Family Peptide Receptor 1) is a G-protein-coupled receptor that relaxin normally activates. When a typical agonist binds RXFP1, it can switch on several downstream pathways at once — including the cAMP pathway and the ERK1/2 pathway. Which pathways fire, and how strongly, shapes the biological response a cell produces.

These pathways do different things. The ERK1/2 branch is associated with the anti-fibrotic, anti-scarring response. The cAMP branch is more closely linked to relaxin’s vascular, hemodynamic and proliferative effects — the ones researchers often want to avoid when isolating the anti-scarring signal.

Infographic text: Relaxin hormone → binds RXFP1 → activates BOTH cAMP (vascular/proliferative) + ERK1/2 (anti-fibrotic). B7-33 → binds RXFP1 → strongly activates ERK1/2 (anti-fibrotic) while largely sparing cAMP. Net effect in models: cleaner anti-scarring signal.

Infographic text (chart): Two bars per pathway — Relaxin shows high cAMP and high ERK1/2; B7-33 shows low cAMP and high ERK1/2. The visual gap on the cAMP bar is the “bias.”

This pathway selectivity is the entire reason the molecule attracts research interest. It is a tool for asking a precise question: what happens to scarred tissue if you switch on relaxin’s anti-fibrotic signal alone?

Key Benefits & Uses of B7-33

The reported B7-33 benefits below all come from preclinical work — isolated cells and rodent models. None have been confirmed in humans. They are summarised here to explain why researchers study the peptide, not to suggest any health outcome.

The Anti-Fibrotic Peptide and Cardiac Remodelling

The headline interest here is its role as an anti-fibrotic peptide. In rodent heart models, relaxin-pathway activation has been linked to reduced collagen deposition and softer, less stiff cardiac tissue. Fibrosis stiffens the heart wall and impairs how efficiently the muscle contracts and relaxes, so a molecule that dials down scarring without raising heart rate or blood pressure is of clear research interest. The biased signalling profile is designed to deliver exactly that combination in the lab.

This is also where the contrast with native relaxin is sharpest. Relaxin’s vascular and proliferative actions complicate any attempt to study its anti-scarring effect in isolation. By muting the cAMP side of the signal, this relaxin analogue lets cardiac researchers attribute observed changes more cleanly to the ERK1/2 pathway.

Lung and Pulmonary Fibrosis

Pulmonary fibrosis — progressive scarring of lung tissue — is another major focus. Preclinical studies of relaxin-pathway agonists have reported reduced markers of lung scarring and remodelling in animal models. Researchers reach for this anti-fibrotic peptide to test whether selective ERK1/2 activation can blunt fibrotic progression in lung tissue without the systemic load of the full hormone. Because lung fibrosis is so difficult to reverse once established, even small experimental signals attract attention in this area.

Kidney and Tissue Remodelling

Renal fibrosis follows many forms of chronic kidney injury, as healthy filtering tissue is gradually replaced by scar. Animal and cell studies of relaxin-receptor activation have explored reductions in kidney scarring and extracellular-matrix buildup. The peptide is used as a probe in this setting to separate the anti-fibrotic effect from relaxin’s broader hemodynamic actions on the kidney, which is exactly the kind of question its pathway bias was built to answer.

Research Interest and Tool-Compound Value

Beyond any single organ, the compound’s biggest value is as a research tool. Its clean pathway selectivity lets scientists test the “ERK1/2 hypothesis” of relaxin’s anti-fibrotic action directly. That makes it useful for mechanistic studies that the bulkier parent hormone cannot easily support — and it explains why interest in the molecule has grown well beyond the heart, where it was first characterised.

B7-33 Side Effects, Safety & Dosage

Because the peptide has never been studied in people, there is no established human safety profile and no validated human dosing protocol. Any discussion of B7-33 side effects is therefore inferred from animal models and from the known pharmacology of the relaxin pathway — not from clinical observation.

The table below summarises observations and theoretical considerations drawn from preclinical literature on relaxin-pathway agonists. Frequencies are qualitative because no human dataset exists.

B7-33 Dosage — Research Context Only

Published B7-33 dosage figures appear only in animal studies and are expressed per kilogram of body weight in rodents (for example, microgram-per-kilogram daily ranges used in mouse fibrosis models such as those reported by Hossain and colleagues). These numbers cannot be converted to a human dose. There is no clinically validated B7-33 protocol, no approved route of administration for humans, and no safety margin established for human use. Researchers should follow their institution’s approved protocols and handle the peptide strictly as a laboratory reagent.

What Does the Research Say?

The B7-33 evidence base is small, recent, and entirely preclinical. The foundational paper is Hossain et al. (2016), which first described the single-chain biased agonist and its anti-fibrotic activity. The table below lists representative published work; readers should consult the primary sources directly.

The takeaway from the literature is consistent: this is a promising research tool for studying anti-fibrotic signalling, with no claims of human benefit. For background on G-protein-coupled receptors and peptide hormones generally, the NCBI literature databases are the authoritative starting point.

B7-33 vs Relaxin and Other Anti-Fibrotic Approaches

How does this relaxin analogue compare to its parent hormone and to other research directions in fibrosis? The table summarises the key differences reported in preclinical work.

The core advantage researchers cite for the peptide over relaxin is the cleaner profile: it isolates the anti-fibrotic ERK1/2 signal while a simpler single-chain structure eases synthesis. It is not “better” in any proven therapeutic sense — it is simply a more focused experimental tool.

How to Use B7-33 — Practical Guidance

This section describes how the peptide is handled in a research setting. It is informational and does not constitute a usage protocol for humans.

Research-grade B7-33 peptide typically ships as a lyophilised (freeze-dried) powder in a sealed vial. Before any laboratory experiment, the powder must be reconstituted, usually with bacteriostatic or sterile water, then stored cold. Because reconstitution math and sterile technique are easy to get wrong, researchers should follow a documented procedure — our peptide reconstitution guide walks through the calculations and steps in detail.

Storage matters: lyophilised peptide is most stable frozen, while reconstituted solution has a much shorter shelf life and should be kept refrigerated and used promptly. Repeated freeze-thaw cycles can degrade a peptide, so many labs aliquot the reconstituted solution into single-use portions. Always work within your institution’s biosafety and handling rules, and label vials clearly with concentration and date.

Quality Markers Researchers Look For

Because this is a research reagent rather than a regulated drug, purity and documentation carry a lot of weight. Researchers typically expect a certificate of analysis, a stated purity figure from a recognised analytical method, and confirmation of the correct molecular mass. Lot-to-lot consistency matters for reproducible experiments, so keeping records of supplier, lot number and storage history is good laboratory practice. None of this changes the core fact that the compound remains unproven in humans.

To explore how the molecule fits alongside other compounds, browse the full research peptides catalogue, our roundup of the best longevity peptides, or our detailed BPC-157 healing and recovery guide for context on how recovery- and repair-focused peptides are studied.

Frequently Asked Questions

What is B7-33?

B7-33 is a 24-amino-acid single-chain peptide derived from the B-chain of the hormone H2 relaxin. It is a relaxin analogue studied preclinically as an anti-fibrotic research compound. It is not a medicine and has never been tested in humans.

What is a biased agonist?

A biased agonist activates one signalling pathway through a receptor while leaving other pathways comparatively inactive. B7-33 is reported to bias RXFP1 toward the anti-fibrotic ERK1/2 pathway while largely sparing the cAMP pathway linked to relaxin’s vascular effects.

Is B7-33 safe?

There is no human safety data for this compound. All B7-33 side effects information comes from animal models and pharmacological inference. It should be treated strictly as a laboratory research reagent, not used by people, and not assumed safe for any human application.

What is the difference between B7-33 and relaxin?

Native relaxin is a two-chain hormone that activates RXFP1 broadly, switching on both ERK1/2 and cAMP pathways. B7-33 is a smaller single-chain analogue that biases signalling toward the anti-fibrotic ERK1/2 pathway, aiming for a cleaner profile in research settings.

What is the B7-33 dosage?

No human B7-33 dosage exists. Published figures come only from rodent studies expressed per kilogram of body weight and cannot be translated to people. There is no validated human protocol or approved route of administration.

What conditions does B7-33 research focus on?

Preclinical B7-33 research centers on fibrosis — scarring of the heart, lungs and kidneys — and on tissue remodelling. These are research questions, not proven uses, and no clinical outcomes have been demonstrated.

Is B7-33 approved by any regulator?

No. The peptide is not approved by any medicines regulator anywhere. It is a research-grade peptide sold for laboratory use only and is not a licensed medicine or dietary supplement.

Where can researchers learn more about RXFP1?

The RXFP1 receptor and relaxin signalling are well documented in the peer-reviewed literature. Start with the Hossain et al. (2016) paper on B7-33 and broader RXFP1 pharmacology reviews indexed on NIH databases.

The Bottom Line

B7-33 is a compelling example of rational peptide design: by trimming relaxin down to its receptor-contacting B-chain and biasing RXFP1 toward the anti-fibrotic ERK1/2 pathway, researchers created a focused tool for studying organ scarring without much of native relaxin’s vascular baggage. The preclinical signals in heart, lung and kidney fibrosis models are genuinely interesting — but they remain just that: preclinical signals in cells and rodents. B7-33 has no human data, no approved dose, and no proven therapeutic role. If you are a qualified researcher, you can explore research-grade B7-33 peptide and the wider peptide range for laboratory study — always under appropriate institutional oversight.

Reviewed by the MedsBase Medical Review Team. Content produced under our editorial policy.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.